Tuesday, October 25, 2011

• Bacterin Study Shows OsteoSponge Equivalence to rhBMP-2 in Spinal Fusion

  BELGRADE, Mont., Oct. 25, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, reported results of a two-year study for OsteoSponge®. Used in conjunction with the patients' own bone marrow aspirate, OsteoSponge is ... read more